EDWARDS (EW) ALERT: Bragar Eagel & Squire, P.C. is Investigating Edwards Lifesciences Corporation on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Edwards Lifesciences Corporation due to a class action complaint related to the company's fiduciary duties and misleading revenue expectations for its TAVR platform [1][2]. Group 1: Legal Investigation - The investigation is focused on long-term stockholders of Edwards who held shares between February 6, 2024, and July 24, 2024, following a class action complaint filed on December 13, 2024 [1]. - The law firm is encouraging affected investors to discuss their legal rights and options [1][5]. Group 2: Financial Performance and Market Reaction - On July 24, 2024, Edwards reported disappointing financial results for Q2 2024, significantly lowering its revenue guidance for the TAVR platform for the full fiscal year [3]. - The company attributed the decline in TAVR performance to increased pressure on hospital workflows from the growth of other structural heart therapies, including its own TMTT [3]. - Following the announcement, Edwards' stock price plummeted from $86.95 to $59.70 per share, marking a decline of approximately 31.34% in one day [4]. Group 3: Company Strategy - During the second quarter, Edwards announced three acquisitions aimed at enhancing treatments alternative to TAVR, indicating a recognition of the potential slowdown in TAVR growth [3].